Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)

v3.22.2
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Income Statement [Abstract]        
Revenues, net $ 29,092 $ 9,142 $ 76,623 $ 24,413
Cost of revenues 10,372 4,676 29,226 11,020
Gross profit 18,720 4,466 47,397 13,393
Operating expenses:        
Diagnostic expenses 1,799 830 6,471 4,639
General and administration 6,306 4,993 14,130 8,775
Research and development 28 93 63 208
Total operating expenses 8,133 5,916 20,664 13,622
Income (loss) from operations 10,587 (1,450) 26,733 (229)
Interest income, net 25 214 98 301
Interest expense (201) (323) (434) (574)
Change in fair value of investment securities 164 (76) 164
Income (loss) from operations before income taxes 10,411 (1,395) 26,321 (338)
Income tax expense (2,965) (6,381)
Income (loss) from operations after income taxes 7,446 (1,395) 19,940 (338)
Net income (loss) 7,446 (1,395) 19,940 (338)
Other comprehensive loss:        
Unrealized loss on marketable debt securities (98) (67) (61) (78)
Total comprehensive income $ 7,348 $ (1,462) $ 19,879 $ (416)
Earnings (loss) per share:        
Basic $ 0.48 $ (0.09) $ 1.28 $ (0.02)
Diluted $ 0.40 $ (0.09) $ 1.07 $ (0.02)
Weighted average common shares outstanding:        
Basic 15,576 15,154 15,531 14,860
Diluted 19,272 15,154 18,964 14,860